COG 133 TFA

• CAT Number: I045813
• CAS Number: 2828432-37-5
• Molecular Formula: C99H182F3N37O21
• Molecular Weight: 2283.78
• Purity: ≥95%

COG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide. COG 133 TFA competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 TFA is also a nAChR antagonist with an IC50 of 445 nM[1][2].
COG 133 (1 mg/kg; intratracheal administration; every other day; for 4 weeks) treatment impairs the resolution of pulmonary fibrosis in mice[3].

Reference

[1]. Orleâncio Gomes R Azevedo, et al. Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis. BMC Gastroenterol. 2012 Jul 13;12:35.
 [Content Brief]

[2]. Elaine A Gay, et al. Apolipoprotein E-derived peptides block alpha7 neuronal nicotinic acetylcholine receptors expressed in xenopus oocytes. J Pharmacol Exp Ther. 2006 Feb;316(2):835-42.
 [Content Brief]

[3]. Huachun Cui, et al. Monocyte-derived alveolar macrophage apolipoprotein E participates in pulmonary fibrosis resolution. JCI Insight. 2020 Mar 12;5(5):e134539.
 [Content Brief]